Observational study of people with fatty liver disease not caused by alcohol
Studies the features, treatment and outlook of adults with nonalcoholic fatty liver disease.
Plain-language title generated from the registry record
Registry title: Observational Study About Patients Diagnosed With NAFLD
Key facts
- Where
- Changsha, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults diagnosed with nonalcoholic fatty liver disease (NAFLD). It is an observational study of how the disease looks, is treated and turns out.
- Age
- 18 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- Diagnosed nonalcoholic fatty liver disease.
Main reasons for not taking part
- Suspected excessive alcohol consumption
- Malignant tumors, dementia, active tuberculosis, AIDS, organ failure, pregnancy or breastfeeding, etc., if the person cannot cooperate with the investigation
- Incomplete data, such as HBV serological results and abdominal ultrasound results
- Refusing to sign informed consent
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT05625750, who can take part
Where in China
- Department of Infectious Disease, Xiangya Hospital, Central South UniversityChangsha, ChinaContact: Yan HuangTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Xiangya Hospital of Central South University
- Trial code
- NCT05625750
- Record updated
- 30 November 2022
- Original description
Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome. The largest study to date using magnetic resonance spectroscopy to quantify liver triglyceride (TG) content showed that approximately 33% of individuals have hepatic steatosis. NAFLD encompasses a continuum of histological findings that starts with steatosis that can progress to nonalcoholic steatohepatitis (NASH), which is characterized by inflammation and cell death, and eventually cirrhosis. Given the large number of individuals afflicted with this condition, there is a clear need to develop effective and safe therapies to treat NAFLD.Read full original descriptionShow less
Study on the Characteristic, Therapy and Prognosis of Patients With Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is the most common condition affecting the liver, owing to its association with obesity and the metabolic syndrome. The largest study to date using magnetic resonance spectroscopy to quantify liver triglyceride (TG) content showed that approximately 33% of individuals have hepatic steatosis. NAFLD encompasses a continuum of histological findings that starts with steatosis that can progress to nonalcoholic steatohepatitis (NASH), which is characterized by inflammation and cell death, and eventually cirrhosis. Given the large number of individuals afflicted with this condition, there is a clear need to develop effective and safe therapies to treat NAFLD.
Inclusion: patients diagnosed with nonalcoholic fatty liver disease.
Exclusion: malignant tumors, dementia, active tuberculosis, AIDS, organ failure, pregnancy or breastfeeding, etc cannot cooperate with the investigation; incomplete data such as HBV serological results and abdominal ultrasound results; patients suspected of excessive alcohol consumption; patients who refuse to sign informed consent.